Dermatology Drugs Market Global Report 2017
出 版 商：TBRC
出版日期：2017/07/17
頁 數：125頁
文件格式：PDF
價 格：
USD 4,000 (Single-User License)
USD 6,000 (Multi-User License)
USD 8,000 (Global-User License)
USD 4,000 (Hard copy)
USD 6,000 (Multi-User License)
USD 8,000 (Global-User License)
USD 4,000 (Hard copy)
Dermatology drugs market include medications that are used for the treatment of skin conditions such as dermatitis (including eczema), rosacea, hyperhidrosis, androgenic alopecia, onychomycosis, hair loss, acne, immune disorders (including psoriasis), microbial infections (bacterial, fungal, and viral), vascular and pigmented lesion removal, common warts, seborrheic keratosis, and other skin diseases.
These drugs can be sold as OTC as well as prescription drugs. Some of the major OTC drugs include Differin, Lamisil, Monistat, and Abreva. Some of the major dermatology prescription drugs include Humira, guselkumab, Abilify, Sovaldi, Harvoni, and Nexium.
The global dermatology drugs market was estimated to be around $31 billion as of 2016. The dermatology drugs market made up around 3% of the overall pharmaceuticals market in 2016. The dermatology drugs market was the thirteenth largest market in the global pharmaceutical market in 2016.
Increase in Mergers and Acquisitions Activity
The market has witnessed multiple strategic initiatives in the recent years. Top companies in the dermatology drugs market strategically acquired start-ups and mid-sized companies to broaden products and services. For instance, LEO Pharma, a Denmark-based company acquired the global dermatology business of Astellas Pharma for $725 million. This deal allows LEO to increase its product portfolio with Astellas Pharma’s dermatology products include Protopic, Locoid, Locobase and Zineryt. Also Piramal Enterprises Ltd, an Indian based company acquired over-the-counter dermatology brand Caladryl in India from Valeant Pharmaceuticals Inc. Through this acquisition Piramal widen its consumer products portfolio in the skin care segment. The process of consolidation in the industry is boosting growth by increasing the marketing and distribution power of dermatology drug companies.
These drugs can be sold as OTC as well as prescription drugs. Some of the major OTC drugs include Differin, Lamisil, Monistat, and Abreva. Some of the major dermatology prescription drugs include Humira, guselkumab, Abilify, Sovaldi, Harvoni, and Nexium.
The global dermatology drugs market was estimated to be around $31 billion as of 2016. The dermatology drugs market made up around 3% of the overall pharmaceuticals market in 2016. The dermatology drugs market was the thirteenth largest market in the global pharmaceutical market in 2016.
Increase in Mergers and Acquisitions Activity
The market has witnessed multiple strategic initiatives in the recent years. Top companies in the dermatology drugs market strategically acquired start-ups and mid-sized companies to broaden products and services. For instance, LEO Pharma, a Denmark-based company acquired the global dermatology business of Astellas Pharma for $725 million. This deal allows LEO to increase its product portfolio with Astellas Pharma’s dermatology products include Protopic, Locoid, Locobase and Zineryt. Also Piramal Enterprises Ltd, an Indian based company acquired over-the-counter dermatology brand Caladryl in India from Valeant Pharmaceuticals Inc. Through this acquisition Piramal widen its consumer products portfolio in the skin care segment. The process of consolidation in the industry is boosting growth by increasing the marketing and distribution power of dermatology drug companies.
1. Dermatology Drugs Market Characteristics;
2. Dermatology Drugs Market Size And Growth;
2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;
3. Pestle Analysis;
3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;
4. Dermatology Drugs Market Customer Information;
5. Dermatology Drugs Market Segmentation;
5.1. Global Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 5.2. Global Dermatology Drugs Market, 2012 - 2020, Historic And Forecast, By Segment; 5.3 Global Dermatology Drugs Market Trends And Strategies;
6. Dermatology Drugs Market Regional And Country Analysis;
6.1. Global Dermatology Drugs Market, 2016, By Region; 6.2. Global Dermatology Drugs Market, 2012 - 2020, Historic And Forecast, By Region; 6.3. Dermatology Drugs Market, 2016, By Country; 6.4. Dermatology Drugs Market, 2012 - 2020, Historic And Forecast, By Country; 6.5. Global Pharmaceutical Market Segments, 2016, By Region; 6.6. Global Pharmaceutical Drugs Market Segments, 2016, By Region; 6.7. Global Pharmaceutical Market Segments, 2016, By Country; 6.8. Global Pharmaceutical Drugs Market Segments, 2016, By Country;
7. Global Dermatology Drugs Market Comparison With Macro Economic Factors;
7.1. Dermatology Drugs Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Dermatology Drugs Expenditure, Global;
8. Dermatology Drugs Market Comparison With Macro Economic Factors Across Countries;
8.1. Dermatology Drugs Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Dermatology Drugs Expenditure, By Country;
9. Dermatology Drugs Market Comparison With Industry Metrics;
9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Dermatology Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Dermatology Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Average Spending On R&D/Product Development, 2016, By Country; 9.6. Global Dermatology Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.8. Global Dermatology Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.9. Prevalent Cases Of Dermatitis, 2014, By Country;
10. Asia-Pacific Dermatology Drugs Market;
10.1.1. Asia-Pacific Dermatology Drugs Market Overview; 10.1.2. Asia-Pacific Dermatology Drugs Historic Market, 2012 - 2016; 10.1.3. Asia-Pacific Dermatology Drugs Forecast Market, 2016 - 2020; 10.1.4. Asia-Pacific Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 10.2. Asia-Pacific Dermatology Drugs Market: Country Analysis; 10.3. China Dermatology Drugs Market; 10.3.1. China Dermatology Drugs Market Overview; 10.3.2. China Dermatology Drugs Historic Market, 2012 - 2016; 10.3.3. China Dermatology Drugs Forecast Market, 2016 - 2020; 10.3.4. China Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 10.3.5. China Dermatology Drugs Percentage Of GDP, 2012 - 2020; 10.3.6. China Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020; 10.4. India Dermatology Drugs Market; 10.4.1. India Dermatology Drugs Market Overview; 10.4.2. India Dermatology Drugs Historic Market, 2012 - 2016; 10.4.3. India Dermatology Drugs Forecast Market, 2016 - 2020; 10.4.4. India Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 10.4.5. India Dermatology Drugs Percentage Of GDP, 2012 - 2020; 10.4.6. India Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020; 10.5. Japan Dermatology Drugs Market; 10.5.1. Japan Dermatology Drugs Market Overview; 10.5.2. Japan Dermatology Drugs Historic Market, 2012 - 2016; 10.5.3. Japan Dermatology Drugs Forecast Market, 2016 - 2020; 10.5.4. Japan Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 10.5.5. Japan Dermatology Drugs Percentage Of GDP, 2012 - 2020; 10.5.6. Japan Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020; 10.6. Australia Dermatology Drugs Market; 10.6.1. Australia Dermatology Drugs Historic Market, 2012 - 2016; 10.6.2. Australia Dermatology Drugs Forecast Market, 2016 - 2020; 10.6.3. Australia Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 10.6.4. Australia Dermatology Drugs Percentage Of GDP, 2012 - 2020; 10.6.5. Australia Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020;
11. Western Europe Dermatology Drugs Market;
11.1.1. Western Europe Dermatology Drugs Market Overview; 11.1.2. Western Europe Dermatology Drugs Historic Market, 2012 - 2016; 11.1.3. Western Europe Dermatology Drugs Forecast Market, 2016 - 2020; 11.1.4. Western Europe Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 11.2. Western Europe Dermatology Drugs Market: Country Analysis; 11.3. UK Dermatology Drugs Market; 11.3.1. UK Dermatology Drugs Market Overview; 11.3.2. UK Dermatology Drugs Historic Market, 2012 - 2016; 11.3.3. UK Dermatology Drugs Forecast Market, 2016 - 2020; 11.3.4. UK Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 11.3.5. UK Dermatology Drugs Percentage Of GDP, 2012 - 2020; 11.3.6. UK Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020; 11.4. Germany Dermatology Drugs Market; 11.4.1. Germany Dermatology Drugs Historic Market, 2012 - 2016; 11.4.2. Germany Dermatology Drugs Forecast Market, 2016 - 2020; 11.4.3. Germany Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 11.4.4 Germany Dermatology Drugs Percentage Of GDP, 2012 - 2020; 11.4.5 Germany Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020; 11.5 France Dermatology Drugs Market; 11.5.1 France Dermatology Drugs Historic Market, 2012 - 2016; 11.5.2 France Dermatology Drugs Forecast Market, 2016 - 2020; 11.5.3 France Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 11.5.4 France Dermatology Drugs Percentage Of GDP, 2012 - 2020; 11.5.5 France Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020; 11.6. Italy Dermatology Drugs Market; 11.6.1. Italy Dermatology Drugs Historic Market, 2012 - 2016; 11.6.2. Italy Dermatology Drugs Forecast Market, 2016 - 2020; 11.6.3. Italy Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 11.6.4. Italy Dermatology Drugs Percentage Of GDP, 2012 - 2020; 11.6.5. Italy Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020; 11.7. Spain Dermatology Drugs Market; 11.7.1. Spain Dermatology Drugs Historic Market, 2012 - 2016; 11.7.2. Spain Dermatology Drugs Forecast Market, 2016 - 2020; 11.7.3. Spain Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 11.7.4. Spain Dermatology Drugs Percentage Of GDP, 2012 - 2020; 11.7.5. Spain Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020;
12. Eastern Europe Dermatology Drugs Market;
12.1.1. Eastern Europe Dermatology Drugs Market Overview; 12.1.2. Eastern Europe Dermatology Drugs Historic Market, 2012 - 2016; 12.1.3. Eastern Europe Dermatology Drugs Forecast Market, 2016 - 2020; 12.1.4 Eastern Europe Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 12.2. Eastern Europe Dermatology Drugs Market: Country Analysis; 12.3. Russia Dermatology Drugs Market; 12.3.1. Russia Dermatology Drugs Historic Market, 2012 - 2016; 12.3.2. Russia Dermatology Drugs Forecast Market, 2016 - 2020; 12.3.3. Russia Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 12.3.4. Russia Dermatology Drugs Percentage Of GDP, 2012 - 2020; 12.3.5. Russia Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020;
13. North America Dermatology Drugs Market;
13.1.1. North America Dermatology Drugs Market Overview; 13.1.2. North America Dermatology Drugs Historic Market, 2012 - 2016; 13.1.3. North America Dermatology Drugs Forecast Market, 2016 - 2020; 13.1.4. North America Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 13.2. North America Dermatology Drugs Market: Country Analysis; 13.3. USA Dermatology Drugs Market; 13.3.1. USA Dermatology Drugs Historic Market, 2012 - 2016; 13.3.1. USA Dermatology Drugs Historic Market, 2012 - 2016; 13.3.2. USA Dermatology Drugs Forecast Market, 2016 - 2020; 13.3.3 USA Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 13.3.4. USA Dermatology Drugs Percentage Of GDP, 2012 - 2020; 13.3.5. USA Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020;
14. South America Dermatology Drugs Market;
14.1.1. South America Dermatology Drugs Market Overview; 14.1.2. South America Dermatology Drugs Historic Market, 2012 - 2016; 14.1.3. South America Dermatology Drugs Forecast Market, 2016 - 2020; 14.1.4. South America Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 14.2. South America Dermatology Drugs Market: Country Analysis; 14.3. Brazil Dermatology Drugs Market; 14.3.1. Brazil Dermatology Drugs Historic Market, 2012 - 2016; 14.3.2. Brazil Dermatology Drugs Forecast Market, 2016 - 2020; 14.3.3. Brazil Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 14.3.4. Brazil Dermatology Drugs Percentage Of GDP, 2012 - 2020; 14.3.5. Brazil Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020;
15. Middle East Dermatology Drugs Market;
15.1.1. Middle East Dermatology Drugs Market Overview; 15.1.2. Middle East Dermatology Drugs Historic Market, 2012 - 2016; 15.1.3. Middle East Dermatology Drugs Forecast Market, 2016 - 2020; 15.1.4. Middle East Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral;
16. Africa Dermatology Drugs Market;
16.1.1. Africa Dermatology Drugs Market Overview; 16.1.2. Africa Dermatology Drugs Historic Market, 2012 - 2016; 16.1.3. Africa Dermatology Drugs Forecast Market, 2016 - 2020; 16.1.4. Africa Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral;
17. Dermatology Drugs Market Competitive Landscape;
17.1. Company Profiles; 17.2. Galderma (Nestle Skin Health); 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Johnson & Johnson; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Abbvie; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. Glaxosmithkline; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Pfizer; 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;
18. Key Mergers And Acquisitions In The Dermatology Drugs Market;
19. Market Background: Pharmaceutical Drugs Market;
19.1.1. Pharmaceutical Drugs Market Characteristics; 19.1.2. Pharmaceutical Drugs Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Drugs Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Drugs Trends And Strategies; 19.2. Pharmaceutical Drugs Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region; 19.2.2. Global Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Drugs Market, 2016, By Country; 19.2.4. Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Country; 19.2.5. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment; 19.2.6. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment; 19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors; 19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global; 19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market;
20. Pharmaceuticals Industry Financial Margins;
21. Appendix;
21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer
2. Dermatology Drugs Market Size And Growth;
2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;
3. Pestle Analysis;
3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;
4. Dermatology Drugs Market Customer Information;
5. Dermatology Drugs Market Segmentation;
5.1. Global Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 5.2. Global Dermatology Drugs Market, 2012 - 2020, Historic And Forecast, By Segment; 5.3 Global Dermatology Drugs Market Trends And Strategies;
6. Dermatology Drugs Market Regional And Country Analysis;
6.1. Global Dermatology Drugs Market, 2016, By Region; 6.2. Global Dermatology Drugs Market, 2012 - 2020, Historic And Forecast, By Region; 6.3. Dermatology Drugs Market, 2016, By Country; 6.4. Dermatology Drugs Market, 2012 - 2020, Historic And Forecast, By Country; 6.5. Global Pharmaceutical Market Segments, 2016, By Region; 6.6. Global Pharmaceutical Drugs Market Segments, 2016, By Region; 6.7. Global Pharmaceutical Market Segments, 2016, By Country; 6.8. Global Pharmaceutical Drugs Market Segments, 2016, By Country;
7. Global Dermatology Drugs Market Comparison With Macro Economic Factors;
7.1. Dermatology Drugs Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Dermatology Drugs Expenditure, Global;
8. Dermatology Drugs Market Comparison With Macro Economic Factors Across Countries;
8.1. Dermatology Drugs Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Dermatology Drugs Expenditure, By Country;
9. Dermatology Drugs Market Comparison With Industry Metrics;
9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Dermatology Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Dermatology Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Average Spending On R&D/Product Development, 2016, By Country; 9.6. Global Dermatology Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.8. Global Dermatology Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.9. Prevalent Cases Of Dermatitis, 2014, By Country;
10. Asia-Pacific Dermatology Drugs Market;
10.1.1. Asia-Pacific Dermatology Drugs Market Overview; 10.1.2. Asia-Pacific Dermatology Drugs Historic Market, 2012 - 2016; 10.1.3. Asia-Pacific Dermatology Drugs Forecast Market, 2016 - 2020; 10.1.4. Asia-Pacific Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 10.2. Asia-Pacific Dermatology Drugs Market: Country Analysis; 10.3. China Dermatology Drugs Market; 10.3.1. China Dermatology Drugs Market Overview; 10.3.2. China Dermatology Drugs Historic Market, 2012 - 2016; 10.3.3. China Dermatology Drugs Forecast Market, 2016 - 2020; 10.3.4. China Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 10.3.5. China Dermatology Drugs Percentage Of GDP, 2012 - 2020; 10.3.6. China Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020; 10.4. India Dermatology Drugs Market; 10.4.1. India Dermatology Drugs Market Overview; 10.4.2. India Dermatology Drugs Historic Market, 2012 - 2016; 10.4.3. India Dermatology Drugs Forecast Market, 2016 - 2020; 10.4.4. India Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 10.4.5. India Dermatology Drugs Percentage Of GDP, 2012 - 2020; 10.4.6. India Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020; 10.5. Japan Dermatology Drugs Market; 10.5.1. Japan Dermatology Drugs Market Overview; 10.5.2. Japan Dermatology Drugs Historic Market, 2012 - 2016; 10.5.3. Japan Dermatology Drugs Forecast Market, 2016 - 2020; 10.5.4. Japan Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 10.5.5. Japan Dermatology Drugs Percentage Of GDP, 2012 - 2020; 10.5.6. Japan Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020; 10.6. Australia Dermatology Drugs Market; 10.6.1. Australia Dermatology Drugs Historic Market, 2012 - 2016; 10.6.2. Australia Dermatology Drugs Forecast Market, 2016 - 2020; 10.6.3. Australia Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 10.6.4. Australia Dermatology Drugs Percentage Of GDP, 2012 - 2020; 10.6.5. Australia Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020;
11. Western Europe Dermatology Drugs Market;
11.1.1. Western Europe Dermatology Drugs Market Overview; 11.1.2. Western Europe Dermatology Drugs Historic Market, 2012 - 2016; 11.1.3. Western Europe Dermatology Drugs Forecast Market, 2016 - 2020; 11.1.4. Western Europe Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 11.2. Western Europe Dermatology Drugs Market: Country Analysis; 11.3. UK Dermatology Drugs Market; 11.3.1. UK Dermatology Drugs Market Overview; 11.3.2. UK Dermatology Drugs Historic Market, 2012 - 2016; 11.3.3. UK Dermatology Drugs Forecast Market, 2016 - 2020; 11.3.4. UK Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 11.3.5. UK Dermatology Drugs Percentage Of GDP, 2012 - 2020; 11.3.6. UK Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020; 11.4. Germany Dermatology Drugs Market; 11.4.1. Germany Dermatology Drugs Historic Market, 2012 - 2016; 11.4.2. Germany Dermatology Drugs Forecast Market, 2016 - 2020; 11.4.3. Germany Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 11.4.4 Germany Dermatology Drugs Percentage Of GDP, 2012 - 2020; 11.4.5 Germany Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020; 11.5 France Dermatology Drugs Market; 11.5.1 France Dermatology Drugs Historic Market, 2012 - 2016; 11.5.2 France Dermatology Drugs Forecast Market, 2016 - 2020; 11.5.3 France Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 11.5.4 France Dermatology Drugs Percentage Of GDP, 2012 - 2020; 11.5.5 France Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020; 11.6. Italy Dermatology Drugs Market; 11.6.1. Italy Dermatology Drugs Historic Market, 2012 - 2016; 11.6.2. Italy Dermatology Drugs Forecast Market, 2016 - 2020; 11.6.3. Italy Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 11.6.4. Italy Dermatology Drugs Percentage Of GDP, 2012 - 2020; 11.6.5. Italy Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020; 11.7. Spain Dermatology Drugs Market; 11.7.1. Spain Dermatology Drugs Historic Market, 2012 - 2016; 11.7.2. Spain Dermatology Drugs Forecast Market, 2016 - 2020; 11.7.3. Spain Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 11.7.4. Spain Dermatology Drugs Percentage Of GDP, 2012 - 2020; 11.7.5. Spain Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020;
12. Eastern Europe Dermatology Drugs Market;
12.1.1. Eastern Europe Dermatology Drugs Market Overview; 12.1.2. Eastern Europe Dermatology Drugs Historic Market, 2012 - 2016; 12.1.3. Eastern Europe Dermatology Drugs Forecast Market, 2016 - 2020; 12.1.4 Eastern Europe Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 12.2. Eastern Europe Dermatology Drugs Market: Country Analysis; 12.3. Russia Dermatology Drugs Market; 12.3.1. Russia Dermatology Drugs Historic Market, 2012 - 2016; 12.3.2. Russia Dermatology Drugs Forecast Market, 2016 - 2020; 12.3.3. Russia Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 12.3.4. Russia Dermatology Drugs Percentage Of GDP, 2012 - 2020; 12.3.5. Russia Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020;
13. North America Dermatology Drugs Market;
13.1.1. North America Dermatology Drugs Market Overview; 13.1.2. North America Dermatology Drugs Historic Market, 2012 - 2016; 13.1.3. North America Dermatology Drugs Forecast Market, 2016 - 2020; 13.1.4. North America Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 13.2. North America Dermatology Drugs Market: Country Analysis; 13.3. USA Dermatology Drugs Market; 13.3.1. USA Dermatology Drugs Historic Market, 2012 - 2016; 13.3.1. USA Dermatology Drugs Historic Market, 2012 - 2016; 13.3.2. USA Dermatology Drugs Forecast Market, 2016 - 2020; 13.3.3 USA Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 13.3.4. USA Dermatology Drugs Percentage Of GDP, 2012 - 2020; 13.3.5. USA Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020;
14. South America Dermatology Drugs Market;
14.1.1. South America Dermatology Drugs Market Overview; 14.1.2. South America Dermatology Drugs Historic Market, 2012 - 2016; 14.1.3. South America Dermatology Drugs Forecast Market, 2016 - 2020; 14.1.4. South America Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 14.2. South America Dermatology Drugs Market: Country Analysis; 14.3. Brazil Dermatology Drugs Market; 14.3.1. Brazil Dermatology Drugs Historic Market, 2012 - 2016; 14.3.2. Brazil Dermatology Drugs Forecast Market, 2016 - 2020; 14.3.3. Brazil Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral; 14.3.4. Brazil Dermatology Drugs Percentage Of GDP, 2012 - 2020; 14.3.5. Brazil Per Capita Average Dermatology Drugs Expenditure, 2012 - 2020;
15. Middle East Dermatology Drugs Market;
15.1.1. Middle East Dermatology Drugs Market Overview; 15.1.2. Middle East Dermatology Drugs Historic Market, 2012 - 2016; 15.1.3. Middle East Dermatology Drugs Forecast Market, 2016 - 2020; 15.1.4. Middle East Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral;
16. Africa Dermatology Drugs Market;
16.1.1. Africa Dermatology Drugs Market Overview; 16.1.2. Africa Dermatology Drugs Historic Market, 2012 - 2016; 16.1.3. Africa Dermatology Drugs Forecast Market, 2016 - 2020; 16.1.4. Africa Dermatology Drugs Market, 2016, By Segment; Antibacterial; Anti-Fungal; Anti-Viral;
17. Dermatology Drugs Market Competitive Landscape;
17.1. Company Profiles; 17.2. Galderma (Nestle Skin Health); 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Johnson & Johnson; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Abbvie; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. Glaxosmithkline; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Pfizer; 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;
18. Key Mergers And Acquisitions In The Dermatology Drugs Market;
19. Market Background: Pharmaceutical Drugs Market;
19.1.1. Pharmaceutical Drugs Market Characteristics; 19.1.2. Pharmaceutical Drugs Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Drugs Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Drugs Trends And Strategies; 19.2. Pharmaceutical Drugs Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region; 19.2.2. Global Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Drugs Market, 2016, By Country; 19.2.4. Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Country; 19.2.5. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment; 19.2.6. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment; 19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors; 19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global; 19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market;
20. Pharmaceuticals Industry Financial Margins;
21. Appendix;
21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer
